What You Should Know:
- Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners.
- Converge Bio's platform uses large language models (LLMs) trained on biological and chemical data (DNA, RNA, protein sequences, and small molecules) to help biotech and pharmaceutical companies discover and develop better-performing drugs in less time.
Converge Bio: Advancing Biotech and Pharma
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
GeneDx Launches Tool to Fuel Rare Disease Drug Discovery
What You Should Know:
- GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.
- The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.
Addressing the Challenges of Drug Development
The traditional drug development process is
Read More
Abbott Opens State-of-the-Art Diabetes Care Manufacturing Facility in Kilkenny, Ireland
What You Should Know:
- Abbott, a global healthcare leader, has officially opened its new global manufacturing center of excellence for Abbott’s diabetes care business in Kilkenny, Ireland.
- Abbott's FreeStyle Libre portfolio is the world's leading continuous glucose monitoring system, helping more than 6 million people with diabetes across over 60 countries.
Boosting Irish Economy and Manufacturing Capabilities
The Kilkenny facility is part of a €440 million
Read More
NVIDIA BioNeMo Framework Accelerates AI Drug Discovery
What You Should Know:
- NVIDIA announced widespread adoption of its open-source BioNeMo™ Framework by pharmaceutical companies, techbio innovators, and AI researchers to accelerate drug discovery and molecule design.
- The framework provides a powerful suite of tools for scaling AI models in biomolecular research, bringing supercomputing capabilities to the forefront of drug development.
Accelerating Drug Discovery with AI
The BioNeMo Framework addresses the growing need
Read More
How Temporal Artery Thermometry Improves Patient Safety Through Accurate Temperature Monitoring
Accurate and frequent temperature monitoring is paramount when it comes to ensuring favorable patient outcomes in the medical community. When a patient is admitted to the hospital, identifying illness or infection quickly has a profound impact on allowing for prompt treatment with antibiotics and can also be critical in the early identification of serious, life-threatening conditions like sepsis.
With the proliferation of less accurate temperature monitoring options during the
Read More
Navigating the Complexities of Preclinical and Clinical Trials
The development of new drugs or medical interventions is a meticulous process involving various stages to ensure safety, efficacy, and regulatory compliance. Central to this journey are the preclinical and clinical trial phases, which are vital for transitioning from laboratory research to clinical application. Let us take a look at the whole process – step by step.
Preclinical Studies: Laying the Groundwork
The preclinical phase involves extensive in vitro (test tube or cell culture) and
Read More
Q/A: Funding Landscape: IPO or Buyout for Life Science Companies?
Life science companies, particularly those heavily invested in research and development, often face critical funding decisions. Should they pursue an initial public offering (IPO) to fuel their growth, or is a strategic buyout from a larger company a more suitable path?
In this exclusive interview, Taylor Wirth, a partner at Barnes & Thornburg, offers his insights on evaluating market conditions, assessing company readiness, and weighing the pros and cons of each funding option. He
Read More
NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development
What You Should Know:
- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.
- This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.
Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery
Genesis Therapeutics, an AI-focused
Read More
Q/A: Medidata VP Talks Overcoming Financial Barriers to Diversity in Clinical Trials
Achieving diversity in clinical trials is crucial for developing effective and safe treatments for all populations. Yet, financial barriers often exclude underrepresented groups from participating, hindering progress towards health equity. This disparity raises critical questions about the accessibility and inclusivity of medical research.
In this insightful Q&A, Meghan Harrington, VP of Clinical Trial Financial Management at Medidata, a Dassault Systèmes brand, sheds light on the
Read More
Medable Unveils Generative AI to Accelerate Clinical Trial Startup
What You Should Know:
- Medable Inc., a leader in clinical development technology, has announced Medable AI, a suite of generative AI capabilities designed to revolutionize the clinical trial startup process. Medable AI empowers sponsors and clinical research organizations (CROs) to build digital and decentralized trials faster, with greater efficiency and control.
- The launch of Medable AI is part of a broader AI strategy for Medable, with plans to expand AI capabilities across its
Read More
